tive pulmonary disease. N Engl J Med 2000; 343:1902–1909 10 Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351:773–780 11 Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus de...

1 Grant I, Heaton RK, McSweeney AJ, et al. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 1982; 142:1470 –1476 2 Antonelli Incalzi R, Gemma A, Marra C, et al. Chronic obstructive pulmonary disease: an original model of cognitive decline. Am Rev Respir Dis 1993; 148:418 – 424 3 Antonelli Incalzi R, Corsonello A, Pedone C, et al. Drawing impairment p...

Chronic obstructive pulmonary disease (COPD) is the most rapidly rising cause of death in individuals >65 yrs of age, the most rapidly growing segment of the USA population. Advancing the clinical research agenda for COPD entails careful consideration of several issues and problems: defining COPD, reliance on physiological testing, outcome measurements and comorbidities. In addition, issues per...